Small molecule compound exhibiting cereblon-binding activity, and use thereof

WO2024205320A3PCT designated stage expired Publication Date: 2024-11-07AEVIS BIO INC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/004074
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-29
Filing Date
2024-03-29
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current cancer treatments targeting cereblon, such as thalidomide and its derivatives, have side effects and limited efficacy, necessitating the development of novel small molecule compounds with specific cereblon-binding activity for enhanced tumor cell killing capabilities.

Method used

Development of a novel small molecule compound with cereblon-binding activity, which acts as a ligand to inhibit cancer cell proliferation and stimulate immune responses, thereby treating various types of cancers, including blood and solid cancers.

Benefits of technology

The compound effectively binds to cereblon, inhibiting cancer cell growth, inducing apoptosis, and activating immune cells, offering a more targeted and effective approach to treating cancers with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

A novel small molecule compound according to the present invention exhibits a very excellent cereblon-binding ability, and thus can act as a novel immunomodulator for treating tumors or cancer diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Low-molecular-weight compound having cereblon binding activity and use thereof

[0001] The present invention relates to a novel low-molecular-weight compound having cereblon binding activity and its use in the treatment of tumors or cancer.

[0002] The ubiquitin-proteasome pathway (UPP) is a crucial pathway that regulates key regulatory proteins and degrades misfolded or abnormal proteins. The UPP is central to numerous cellular processes, and its defects or imbalance can lead to the development of various diseases. Covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases. These ligases comprise over 500 different proteins and are classified into several classes defined by structural elements of their E3 functional activity.

[0003] Cereblon (CRBN) interacts with damaged DNA binding protein 1 (DDB1) and forms the DDB1-CUL4a-Roc1 ubiquitin ligase complex with Cullin 4, and proteins recognized by CRBN by these complexes function as substrate receptors that can be ubiquitinated and degraded by the proteasome.

[0004] Cereblon (CRBN) is known as a molecular target of immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide (Lopez-Girona et al.; Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26:2326-2335). Specifically, thalidomide, a drug approved for the treatment of multiple myeloma in the late 1990s, binds to cereblon and binds to CRL4. CRBN Modulating the substrate specificity of the ubiquitin ligase complex underlies the pleiotropic effects of thalidomide on immune cells and cancer cells. However, with the reported side effects of thalidomide, various studies have been conducted to develop analogues with higher efficacy and fewer side effects as a means of utilizing it as an anticancer treatment, and cereblon modulators such as lenalidomide, pomalidomide, CC-220, CC-122, CC-885, and TD-106 have been developed, and their clinical applicability has been demonstrated in hematological malignancies such as multiple myeloma, myelodysplastic syndrome lymphoma, and leukemia (Le Roy A et al.: Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Front Immunol. 2018; 9: 977).

[0005] The antitumor activity of cereblon modulators is mediated by:

[0006] 1) Inhibition of cancer cell proliferation and induction of apoptosis,

[0007] 2) Discontinuation of nutritional support from the tumor stroma;

[0008] 3) Proliferation of T cells, production of cytokines, and activation of NK (natural killer) cells due to stimulation of immune cells.

[0009] Accordingly, the inventors of the present invention have endeavored to develop a novel low-molecular weight compound that has substrate specificity for cereblon and can effectively kill tumor cells, and as a result, have completed the present invention by developing a novel low-molecular weight compound that acts as a cereblon ligand useful for treating tumors or cancer.

[0010] The present invention aims to provide a novel compound having binding activity to cereblon and a use thereof.

[0011] To achieve the above object, the present invention provides any one compound shown in Table 1, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.

[0012] In the present invention, the compound, its optical isomer, its racemic mixture, its hydrate, its solvate or its pharmaceutically acceptable salt may be characterized by having cereblon binding affinity.

[0013] The present invention also provides a pharmaceutical composition for preventing or treating a benign tumor or cancer, comprising the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

[0014] In the present invention, the cancer may be characterized as being a blood cancer or a solid cancer.

[0015] In the present invention, the blood cancer may be characterized as being selected from the group consisting of acute leukemia, chronic leukemia, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

[0016] In the present invention, the solid cancer may be characterized by being selected from the group consisting of melanoma, myoma, multiple myeloma, head and neck cancer, nasopharyngeal cancer, esophageal cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, stomach cancer, bladder cancer, colon cancer, colon cancer, rectal cancer, small intestine cancer, anal cancer, liver cancer, gallbladder cancer, bile duct cancer, biliary tract cancer, pancreatic cancer, thyroid cancer, parathyroid cancer, lung cancer, breast cancer, ovarian cancer, fallopian tube cancer, uterine cancer, vaginal cancer, vulvar cancer, penile cancer, kidney cancer, adrenal cancer, urothelial cancer, prostate cancer, testicular tumor, bone soft tissue sarcoma, skin cancer, glioma, brain tumor, spinal tumor, Kaposi sarcoma, squamous cell carcinoma, pleural mesothelioma, and primary peritoneal cancer.

[0017] The present invention also provides a composition for inhibiting cereblon activity comprising the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, or a solvate thereof.

[0018] The present invention also provides a method for preventing or treating a disease associated with cereblon activity, such as a benign tumor or cancer, comprising administering the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof to a patient in need thereof.

[0019] The present invention also provides a use of the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof for the prevention or treatment of diseases associated with cereblon activity, such as benign tumors or cancer.

[0020] The present invention also provides the use of the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of a disease associated with cereblon activity, such as a benign tumor or cancer.

[0021] The compound according to the present invention has excellent binding affinity to cereblon and can act as a novel immunomodulator for treating tumors or cancer diseases.

[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In general, the nomenclature used herein and the experimental methods described below are well known and commonly used in the art.

[0023]

[0024] In the present invention, compounds having excellent binding affinity to cereblon were selected and their tumor cell killing effect was confirmed.

[0025]

[0026] Accordingly, the present invention provides, in one aspect, any one of the compounds shown in Table 1, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.

[0027]

[0028] The compound according to the present invention can be prepared and used in the form of a prodrug, hydrate, solvate, and pharmaceutically acceptable salt to enhance absorption in the body or increase solubility, and therefore the prodrug, hydrate, solvate, and pharmaceutically acceptable salt also fall within the scope of the present invention. In addition, since the compound has a chiral carbon, its stereoisomers exist, and such stereoisomers are also included within the scope of the present invention.

[0029] The term "prodrug" refers to a substance that is transformed into the parent drug in vivo. Prodrugs are often used because, in some cases, they are easier to administer than the parent drug. For example, they may be bioactive by oral administration, whereas the parent drug may not be. Prodrugs may also have improved solubility in pharmaceutical compositions compared to the parent drug. For example, prodrugs may be biohydrolyzable esters of compounds according to the present invention and pharmaceutically acceptable salts thereof. Another example of a prodrug may be a short peptide (polyamino acid) linked to an acid group that is metabolized to reveal the active site of the peptide.

[0030] The term "hydrate" means a compound of the present invention or a salt thereof containing a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

[0031] The term "solvate" refers to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents include those that are volatile, non-toxic, and / or suitable for human administration.

[0032] The term "isomer" refers to a compound of the present invention or a salt thereof that has the same chemical formula or molecular formula but is structurally or sterically different. Such isomers include structural isomers such as tautomers, stereoisomers such as R or S isomers with an asymmetric carbon center, and geometric isomers (trans, cis). All of these isomers and mixtures thereof are also included within the scope of the present invention.

[0033] The term "pharmaceutically acceptable salt" means a salt form of a compound that does not cause serious irritation to the organism to which the compound is administered and does not impair the biological activity and physical properties of the compound. The pharmaceutical salts include acid addition salts formed by acids that form non-toxic acid addition salts containing pharmaceutically acceptable anions, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, etc.; organic carboxylic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc.; sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. For example, pharmaceutically acceptable carboxylic acid salts include metal salts or alkaline earth metal salts formed by lithium, sodium, potassium, calcium, magnesium, etc.; amino acid salts such as lysine, arginine, guanidine, etc.; organic salts such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline, and triethylamine, etc. The compound according to the present invention can be converted into its salt by a conventional method.

[0034]

[0035] From another aspect, the present invention relates to a pharmaceutical composition for preventing or treating benign tumors or cancer, comprising the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

[0036] In the present invention, the cancer may be characterized as being a blood cancer or a solid cancer.

[0037] In the present invention, the blood cancer may be characterized by being selected from the group consisting of acute leukemia, chronic leukemia, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma, but is not limited thereto.

[0038] In the present invention, the solid cancer may be characterized by being selected from the group consisting of melanoma, myoma, multiple myeloma, head and neck cancer, nasopharyngeal cancer, esophageal cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, stomach cancer, bladder cancer, colon cancer, colon cancer, rectal cancer, small intestine cancer, anal cancer, liver cancer, gallbladder cancer, bile duct cancer, biliary tract cancer, pancreatic cancer, thyroid cancer, parathyroid cancer, lung cancer, breast cancer, ovarian cancer, fallopian tube cancer, uterine cancer, vaginal cancer, vulvar cancer, penile cancer, kidney cancer, adrenal cancer, urothelial cancer, prostate cancer, testicular tumor, bone soft tissue sarcoma, skin cancer, glioma, brain tumor, spinal tumor, Kaposi sarcoma, squamous cell carcinoma, pleural mesothelioma, and primary peritoneal cancer, but is not limited thereto.

[0039]

[0040] In the present invention, the term "pharmaceutical composition" or "pharmaceutical formulation" means a mixture comprising a pharmaceutically acceptable excipient, such as a diluent or carrier, which makes the novel compound of the present invention particularly suitable for in vivo or in vitro diagnostic or therapeutic use. In some embodiments, a pharmaceutical composition comprising a composition of the present invention can be provided by a method for administering a therapeutically effective amount to a subject as needed. In some embodiments, a composition of the present invention can be administered to a human.

[0041] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a compound or composition (e.g., a compound or composition of the present invention) sufficient to achieve a beneficial or desired result. An effective amount may be administered in one or more doses, applications, or dosages and is not intended to be limited to a particular formulation or route of administration.

[0042] While the pharmaceutical compositions provided in the present invention are principally intended for administration to humans, those skilled in the art will appreciate that such compositions are generally suitable for administration to all types of animals. That is, the pharmaceutical compositions according to the present invention can also be administered to other mammals, such as animals requiring veterinary treatment, such as livestock (e.g., dogs, cats, etc.), farm animals (e.g., cows, sheep, pigs, horses, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.). A skilled veterinary pharmacologist, with a thorough understanding of the modifications of pharmaceutical compositions for administration to various animals, can design and / or implement such modifications simply through routine experimentation, if necessary.

[0043] The pharmaceutical compositions described herein may be prepared by any method known in the art of pharmacology or described herein. Typically, such methods for preparing tablets involve the steps of bringing the active ingredient into association with excipients and / or one or more other auxiliary ingredients, followed by, if necessary or desired, shaping and / or packaging the product into desired single- or multi-dose units.

[0044] The pharmaceutical compositions of the present invention may be manufactured, packaged, and / or sold unpackaged as single unit doses and / or multiple single unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient administered to a subject and / or a convenient fraction of such a dosage, such as, for example, one-half or one-third of the dosage.

[0045] The relative amounts of the active ingredient, pharmaceutically acceptable excipients, and / or any additional ingredients in the pharmaceutical compositions of the present invention will vary depending on the identity, size, and / or disorder of the subject being treated and the route by which the composition is administered. For example, the composition may comprise from 0.001% to 100% (w / w) active ingredient.

[0046] As used herein, pharmaceutically acceptable excipients include any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersing or suspending aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, and the like suitable for a particular dosage form purpose. Remington's publication [The Science and Practice of Pharmacy, 21st Edition, AR Gennaro, (Lippincott, Williams & Wilkins, Baltimore, MD, 2006]] discloses various excipients used in the preparation of pharmaceutical compositions and known techniques for their preparation. Except that any conventional carrier medium is incompatible with the substance or its derivatives, e.g., by providing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component of the pharmaceutical composition, its use is contemplated as being within the scope of the present invention. Pharmaceutically acceptable excipients are at least 95%, 96%, 97%, 98%, 99%, or 100% pure.

[0047] The above excipients are approved for human and veterinary use. In some embodiments, the excipients are approved by the U.S. Food and Drug Administration. In some embodiments, the excipients are pharmaceutical grade. In some embodiments, the excipients meet the standards of the United States Pharmacopeia (USP), European Pharmacopeia (EP), British Pharmacopeia, and / or International Pharmacopeia (EP).

[0048] These excipients may optionally be included in the formulations of the present invention. Excipients such as cocoa butter and suppository wax, colorants, coating agents, sweeteners, flavoring agents, and perfumes may be present in the compositions at the discretion of the formulator.

[0049] Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and combinations thereof.

[0050] Exemplary granulating and / or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (Starch 1500), microcrystalline starch, water-insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Vegum), sodium lauryl sulfate, quaternary ammonium compounds, and combinations thereof.

[0051] Exemplary surface active agents and / or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan gum, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and veegum [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., carboxymethylcellulose sodium, powdered cellulose, Hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g., polyoxyethylene monostearate [Miruz 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Breeze 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laureate, sodium lauryl sulfate, Pluronic F 68,including but not limited to poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and / or combinations thereof.

[0052] Exemplary binders include, but are not limited to, starches (e.g., corn starch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic gums (e.g., acacia, sodium alginate, extracts of Irish moss, panwar gum, shattie gum, mucilage of Isaphol fuskus, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (veegum), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohols; and combinations thereof.

[0053] Exemplary preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives. Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and trisodium edetate. Exemplary antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal. Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid. Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol. Exemplary acid preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxymethylene mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Fenonib, methylparaben, Germoll 115, Germaben II, Neolon, Carton, and Euxyl. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.

[0054] Exemplary buffers include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium globionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixture, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, Pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and combinations thereof, including but not limited to.

[0055] Exemplary lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.

[0056] Exemplary oils include almond, apricot kernel, avocado, babassu palm, bergamot, black currant seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, flax seed, geraniol, pumpkin, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litchia cubeba, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange-colored orange raffi, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquamana, savory, sea buckthorn, Examples of oils include, but are not limited to, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.

[0057] Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may also contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizers, and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (particularly, cottonseed, peanut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions may include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, and perfumes. In certain embodiments for parenteral administration, the novel compounds of the present invention are mixed with solubilizing agents such as cremophor, alcohols, oils, denatured oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.

[0058] Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be prepared according to the known art using dispersing or wetting agents and suspending agents. The sterile injectable preparation may be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, such as 1,3-butanediol. Acceptable vehicles and solvents include water, Ringer's solution, USP, and isotonic sodium chloride solution. Sterile, fixed oils are also commonly employed as a solvent or suspending medium. Any bland fixed oil, including synthetic mono- or diglycerides, may be employed for this purpose. Fatty acids, such as oleic acid, are also used in the preparation of injectables.

[0059] Injectable preparations may be sterilized, for example, by filtration through a bacteria-retaining filter, or by including a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable medium before use.

[0060] To prolong the effect of a drug, it is often desirable to slow its absorption from subcutaneous or intramuscular injection. This is achieved by using liquid suspensions of crystalline or amorphous substances with low water solubility. The rate of drug absorption then ultimately depends on the dissolution rate, which can be influenced by crystal size and crystalline form. Alternatively, delayed absorption of parenteral drugs is achieved by dissolving or suspending the drug in an oil vehicle.

[0061] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient may be mixed with one or more inert pharmaceutically acceptable excipients or carriers such as sodium citrate or dicalcium phosphate and / or a) fillers or bulking agents such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) dissolution retarder agents such as paraffin, f) absorption promoters such as quaternary ammonium compounds, g) humectants such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, It is mixed with magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof.

[0062] For capsules, tablets, and pills, dosage forms may include buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose, as well as high molecular weight polyethylene glycols. Solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical compounding art. These may optionally include opacifying agents and may be compositions that release the active ingredient only, or preferentially, to a specific portion of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that may be employed include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose, as well as high molecular weight polyethylene glycols.

[0063] The active ingredient may be microencapsulated with one or more of the excipients described above. Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, release-controlled coatings, and other coatings well known in the pharmaceutical compounding art. In these solid dosage forms, the active ingredient may be mixed with one or more inert diluents, such as sucrose, lactose, or starch. These dosage forms may include additional substances other than inert diluents, as is customary practice, such as tablet lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms may also include buffering agents. These may optionally include opacifying agents and may be compositions that release the active ingredient solely, or preferentially, into a specific part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that may be used include polymeric substances and waxes.

[0064] Dosage forms for topical and / or transdermal administration of the novel compounds of the present invention or pharmaceutical compositions containing them may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and / or patches. Typically, the active ingredient is mixed with a pharmaceutically acceptable carrier and / or any necessary preservatives and / or buffers as may be required under sterile conditions. Additionally, the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of the active ingredient into the body. Such dosage forms can be prepared, for example, by dissolving and / or dispersing the active ingredient in a suitable medium. Alternatively or additionally, rate control may be achieved by providing a rate-controlling membrane and / or dispersing the active ingredient in a polymer matrix and / or gel.

[0065] Formulations for topical administration include, but are not limited to, liquid and / or semi-liquid preparations such as liniments, lotions, oil-in-water and / or water-in-oil emulsions such as creams, ointments and / or pastes, and / or solutions and / or suspensions. Topically administrable preparations may contain, for example, from about 1% to about 10% (w / w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more additional ingredients described herein.

[0066] The novel compounds of the present invention described herein or pharmaceutical compositions containing them are typically prepared in dosage unit form for easy and uniform administration. However, it will be understood that the total daily dosage of the compositions of the present invention will be determined by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dosage level for any particular subject will depend on a variety of factors, including the disease, disorder, or disorder being treated and its severity; the activity of the specific active ingredient employed; the specific composition employed; the age, weight, general health, sex, and diet of the subject; the time of administration, route of administration, and excretion rate of the specific active ingredient employed; the duration of treatment; medications used in combination or concurrently with the specific active ingredient employed; and other factors well known in the medical arts.

[0067] The novel compounds of the present invention, salts thereof, or pharmaceutical compositions thereof may be administered by any route. In some embodiments, the novel compounds, salts thereof, or pharmaceutical compositions thereof are administered by various routes, including orally, intravenously, intramuscularly, intraarterially, intramedullary, intrathecally, subcutaneously, intracerebroventricularly, transdermally, intradermally, rectally, intravaginally, intraperitoneally, topically (by powders, ointments, creams, and / or drops), mucosally, nasally, orally, enterally, sublingually; by intratracheal instillation, bronchial instillation, and / or by inhalation; and / or by oral spray, nasal spray, and / or aerosol. Routes specifically contemplated are invasive intravenous injection, local administration via the blood and / or lymphatic supply, and / or direct administration to the affected area. In general, the most appropriate route of administration will depend on a variety of factors, including the properties of the agent (e.g., stability in the gastrointestinal environment) and the impairment of the subject (e.g., whether the subject can tolerate oral administration).

[0068] In certain embodiments, the novel compounds of the present invention, salts thereof, or pharmaceutical compositions thereof may be administered at a dosage level sufficient to deliver from about 0.001 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 50 mg / kg, from about 0.1 mg / kg to about 40 mg / kg, from about 0.5 mg / kg to about 30 mg / kg, from about 0.01 mg / kg to about 10 mg / kg, from about 0.1 mg / kg to about 10 mg / kg, or from about 1 mg / kg to about 25 mg / kg of body weight of the subject once or more per day to achieve the desired therapeutic effect. The desired dosage may be delivered three times daily, twice daily, daily, every other day, every three days, weekly, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered via multiple administrations (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more administrations).

[0069] It will be understood that the dosage ranges described herein provide guidance for administering the pharmaceutical compositions to adults. For example, the dosage administered to children or adolescents can be determined by a physician or one skilled in the art, and may be less than or equal to that administered to adults. The precise amount of the peptide according to the present invention required to achieve an effective dose will vary from subject to subject, depending on, for example, the subject's species, age, overall disorder, side effects, or severity of the disorder, the identity of the specific compound, the route of administration, and other factors.

[0070] It will be appreciated that the novel compounds and pharmaceutical compositions of the present invention may be used in combination therapy. The specific combination of treatments (therapeutics or procedures) to be used in combination therapy will take into account the desired therapeutic effect to be achieved and the suitability of the desired therapeutic agents and / or procedures.

[0071] The pharmaceutical compositions of the present invention may be administered alone or in combination with one or more therapeutically active agents. The term "combination" is not intended to imply that the agents must be administered at the same time and / or formulated for co-delivery, although the following delivery methods are within the scope of the present invention. The compositions may be administered simultaneously with, prior to, or subsequent to, one or more other therapeutic agents or medical procedures. Typically, each agent will be administered at the dosage and / or time schedule established for that agent. Additionally, the present invention encompasses delivering the pharmaceutical compositions of the present invention in combination with agents capable of improving their bioavailability, reducing and / or modifying their metabolism, inhibiting their secretion, and / or modifying their distribution within the body. It will be further understood that the novel compounds of the present invention and the therapeutically active agents used in this combination may be administered together in a single composition or separately in different compositions.

[0072] The specific combination used in combination therapy will take into account the desired therapeutic effect to be achieved and / or the suitability of the procedures and / or therapeutically active agents comprising the peptides of the present invention. It will be appreciated that the combination employed may achieve the desired effect for the same disorder (e.g., the novel compounds of the present invention may be administered in combination with another therapeutically active agent (e.g., a second therapeutic agent) used to treat the same disorder), and / or they may achieve different effects (e.g., controlling any side effects).

[0073] As used herein, "therapeutically active agent" refers to any substance used as a medicine to treat, prevent, delay, reduce or improve a disorder, and refers to a substance used in treatment, including preventive and curative treatments.

[0074] In some embodiments, the other therapeutically active agent for combination administration is for treating multiple myeloma. In some embodiments, the other therapeutically active agent may be a proteasome inhibitor and / or an immune-modifying drug. In the present invention, the other therapeutically active agent may be selected from the group consisting of, but is not limited to, dexamethasone, bortezomib, carfilzomib, melphalan, doxorubicin, and cyclophosphamide.

[0075] In some embodiments, the pharmaceutical compositions of the present invention may be administered in combination with any therapeutically active agent or procedure (e.g., surgery, radiation therapy) useful for treating, alleviating, ameliorating, alleviating, delaying the onset, inhibiting the progression, reducing the severity, and / or reducing the incidence of one or more symptoms or characteristics.

[0076]

[0077] In one aspect, the present invention can be provided as a kit for treating a subject suffering from a tumor or cancer disease.

[0078] In some embodiments, the kit comprises i) instructions for administering a novel compound or pharmaceutical composition according to the invention to a subject suffering from the disease, and ii) a novel compound or pharmaceutical composition according to the invention. In some embodiments, the kit may comprise one or more unit dosage forms containing a dose of the novel compound or pharmaceutical composition as described herein that is effective for treating the disease in the subject. In some embodiments, the subject is a human patient.

[0079] In some embodiments, the kit further comprises one or more selected from the group consisting of a sterile syringe, a sterile needle, a sterile IV bag, an infusion pump, or any combination thereof.

[0080] The term "about" as used herein can be interpreted to mean approximately, roughly, roughly, or to a certain degree. When the term "about" is used with a numerical range, it is interpreted to modify the range by extending the boundaries above and below the specified numerical value. Generally, the term "about" is used herein to modify numerical values ​​above and below the specified value by a 10% variance.

[0081] “Individual,” “patient,” and “subject” are used interchangeably and include any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, or primates, including humans.

[0082] As used herein, "treatment" means, unless otherwise stated, reversing, alleviating, inhibiting the progression of, or preventing a disease or disorder to which the term applies, or one or more symptoms of the disease or disorder. As used herein, the term "treatment" refers to the act of treating when "treating" is defined as above. Therefore, in mammals, "treatment" or "therapy" of a disease may include one or more of the following:

[0083] (1) Preventing the development of disease;

[0084] (2) Prevent the spread of disease;

[0085] (3) Alleviate disease;

[0086] (4) Preventing recurrence of disease and

[0087] (5) Alleviating the symptoms of the disease (palliating)

[0088] In the present invention, unless otherwise stated, “prevention” means any act of suppressing or delaying the onset of the disease by administering a pharmaceutical composition according to the present invention.

[0089]

[0090] In addition, it is obvious that the compound of Table 1 according to the present invention can be easily prepared by a person skilled in the art and can be easily modified by a person skilled in the art depending on a specific substituent.

[0091]

[0092] In another aspect, the present invention relates to a cereblon activity inhibitor or a composition for inhibiting cereblon activity comprising the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof or a solvate thereof.

[0093] In one embodiment, the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a salt thereof can be provided as an experimental reagent used to inhibit cereblon activity in vitro.

[0094]

[0095] In another aspect, the present invention provides a method for preventing or treating a disease associated with cereblon activity, such as a benign tumor or cancer, comprising administering to a patient in need thereof the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.

[0096] The present invention also provides a use of the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof for the prevention or treatment of diseases associated with cereblon activity, such as benign tumors or cancer.

[0097] The present invention also provides the use of the compound, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of a disease associated with cereblon activity, such as a benign tumor or cancer.

[0098]

[0099] Hereinafter, the present invention will be described in more detail through examples. However, the following examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention.

[0100]

[0101] Example 1. In vitro CRBN binding assay

[0102]

[0103] Thalidomide compounds are known to bind to the E3 ligase cereblon (CRBN) and degrade its substrates, the transcription factors Aiolos and Ikaros, thereby regulating immune cell function and exerting various pharmacological effects. Therefore, the cereblon-binding capacity of various compounds was compared in vitro.

[0104]

[0105] The binding affinity to cereblon was measured using the 'AlphaScreen' method based on Fluorescence Resonance Energy Transfer (FRET). The test was performed using the PROTAC Optimization kit for BET Bromodomain-Cereblon binding kit (#79770, BPS bioscience, CA USA) according to the 'Competitive Inhibition of the PROTAC assay' described in the kit manual. All reagents except the candidate substance, DMSO, and Flag / Glutathione beads (#6765300, PerkinElmer, USA) were included in the kit.

[0106]

[0107] As a result, compounds having cereblon binding activity as shown in Table 1 were identified.

[0108]

[0109] [Table 1]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

Claims

1. Any one of the compounds shown in Table 1, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof: [Table 1] 2. In the first paragraph, the compound, its optical isomer, its racemic mixture, its hydrate, its solvate or its pharmaceutically acceptable salt, characterized in that it has cereblon binding affinity, the compound, its optical isomer, its racemic mixture, its hydrate, its solvate or its pharmaceutically acceptable salt:

3. A pharmaceutical composition for the prevention or treatment of a benign tumor or cancer, comprising as an active ingredient a compound of paragraph 1 or 2, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition for preventing or treating a benign tumor or cancer, characterized in that the cancer in the third paragraph is a blood cancer or a solid cancer.

5. A pharmaceutical composition for preventing or treating a benign tumor or cancer, characterized in that in paragraph 4, the blood cancer is selected from the group consisting of acute leukemia, chronic leukemia, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

6. In paragraph 4, A pharmaceutical composition for preventing or treating a benign tumor or cancer, characterized in that the solid cancer is selected from the group consisting of melanoma, myoma, multiple myeloma, head and neck cancer, nasopharyngeal cancer, esophageal cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, stomach cancer, bladder cancer, colon cancer, colon cancer, rectal cancer, small intestine cancer, anal cancer, liver cancer, gallbladder cancer, bile duct cancer, biliary tract cancer, pancreatic cancer, thyroid cancer, parathyroid cancer, lung cancer, breast cancer, ovarian cancer, fallopian tube cancer, uterine cancer, vaginal cancer, vulvar cancer, penile cancer, kidney cancer, adrenal cancer, urothelial cancer, prostate cancer, testicular tumor, bone soft tissue sarcoma, skin cancer, glioma, brain tumor, spinal tumor, Kaposi sarcoma, squamous cell carcinoma, pleural mesothelioma, and primary peritoneal cancer.

7. A composition for inhibiting cereblon activity, comprising a compound of claim 1 or 2, an optical isomer thereof, a racemic mixture thereof, a hydrate thereof, or a solvate thereof.

Citation Information

Patent Citations

  • Small molecules against cereblon to enhance effector t cell function

    KR1020180125521A

  • Imide-based modulators of proteolysis and associated methods of use

    US20160058872A1

  • C3-carbon linked glutarimide degronimers for target protein degradation

    WO2017197046A1

  • CRBN ligands and uses thereof

    WO2019140387A1